Business Context and Reporting Period
Company: Varex Imaging Corp (VREX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended July 3, 2026
Business Overview: Varex designs, manufactures, and sells X-ray imaging components for medical (CT, mammography, dental) and industrial (security, non-destructive testing) applications. The company operates two segments: Medical and Industrial.
Key Financial Metrics
| Metric (in millions) | Q3 2026 | Q3 2025 | 9M 2026 | 9M 2025 |
|---|---|---|---|---|
| Revenues, Net | $210.5 | $203.0 | $636.1 | $615.7 |
| Gross Profit | $76.7 | $67.5 | $219.1 | $212.7 |
| Gross Margin | 36.4% | 33.3% | 34.4% | 34.5% |
| Operating Income | $22.8 | $(80.7) | $52.6 | $(47.4) |
| Net Income (Attributable to Varex) | $15.7 | $(89.1) | $9.9 | $(82.5) |
| Diluted EPS | $0.37 | $(2.15) | $0.23 | $(2.00) |
| Cash and Equivalents | $99.2 | $145.0 | $99.2 | $145.0 |
| Total Debt (Net) | $347.1 | $367.5 | $347.1 | $367.5 |
| Operating Cash Flow (9M) | $3.4 | $33.8 | $3.4 | $33.8 |
Material Changes vs. Prior Period
- Profitability Turnaround: The company returned to profitability in Q3 2026 ($15.7M net income) compared to a significant loss in Q3 2025 ($89.1M). The prior year loss was heavily impacted by a $93.9M goodwill impairment charge in the Medical segment, which did not recur in the current period.
- Revenue Growth: Total revenue increased 3.7% year-over-year in Q3. The Industrial segment drove growth with a 25.6% increase, while the Medical segment declined 5.7%.
- Debt Refinancing: In Q2 2026, the company refinanced its debt structure, entering a new Credit and Guaranty Agreement. This involved issuing a $350M Term Loan and repaying $368M of Senior Secured Notes, resulting in a $9.4M loss on debt extinguishment but lower overall interest rates.
- Tariff Refunds: The company received approximately $17.0M in IEEPA tariff refunds, which reduced cost of revenues and improved gross margin. However, the company also recorded a $6.6M liability to reimburse customers for previously collected tariff surcharges.
- Inventory Build: Inventories increased to $347.1M from $299.4M at the end of the prior fiscal year, reflecting a strategic build-up for anticipated future demand.
Guidance, Outlook, and Risks
- Proposed Acquisition: On August 10, 2026, Varex entered into a definitive agreement to be acquired by Teledyne Technologies Incorporated for $18.90 per share in cash. The transaction is expected to close in early 2027, subject to regulatory approvals and shareholder vote. A termination fee of $25.3M applies under certain conditions.
- Trade Environment: The company faces ongoing volatility from tariffs and trade policies. While IEEPA tariffs were invalidated, new Section 301 tariffs (12.5% on China) and Section 338 duties (50% on Canada) have been or are being imposed. The company is monitoring the impact of these measures on costs and customer demand.
- Customer Concentration: One customer (Canon Medical Systems) accounted for 15.3% of Q3 revenue. The top 10 customers collectively accounted for approximately 53% of revenue.
- Liquidity: As of July 3, 2026, the company had $91.3M available under its Revolving Credit Facility. Management believes current cash flows and liquidity are sufficient for the next 12 months.
Investor Verification Checklist
- Merger Completion: Verify the status of regulatory approvals and shareholder voting for the Teledyne acquisition, as failure to close could impact stock price and strategic direction.
- Tariff Exposure: Assess the net impact of new Section 301 and Section 338 tariffs on future gross margins, particularly given the company's reliance on global supply chains and exports.
- Debt Covenants: Review compliance with the new Credit Facility covenants, specifically the consolidated total net leverage ratio (max 4.25:1.00 through Sept 2027) and fixed charge coverage ratio.
- Customer Concentration: Monitor the stability of the top 10 customers, which represent over half of total revenue, and any potential shifts in OEM demand.
- Inventory Levels: Track the conversion of the increased inventory ($347.1M) into revenue to ensure no significant write-downs are required if demand softens.